Introduction
Alzheimer’s Disease (AD) research typically pursues two parallel goals: clinical diagnosis—classifying patients as healthy, having Mild Cognitive Impairment (MCI), or having AD—and association discovery, which identifies genetic markers linked to physical brain changes. Historically, these tasks have been treated as independent. However, they are biologically coupled: the genetic factors driving disease progression are the same ones manifesting as structural changes in the brain.
Traditional approaches often struggle with data heterogeneity—combining discrete Single Nucleotide Polymorphisms (SNPs) with continuous MRI features—and frequently ignore the ordinal nature of AD progression. This paper introduces a unified Sparse Bayesian Multiview Learning framework that bridges these gaps, treating diagnosis and biomarker discovery as a single, integrated task.
Methodology: A Unified Bayesian Framework
The proposed model assumes that genetic data and imaging data are generated from a shared set of "latent features" representing a patient's underlying biological state.
Key technical innovations include:
- Common Latent Space: Maps heterogeneous inputs (SNPs and MRI) into a shared representation.
- Ordinal Regression: Accounts for the natural progression of AD (Normal $\rightarrow$ MCI $\rightarrow$ AD) rather than treating it as a standard classification problem.
- Spike-and-Slab Priors: Implements Bayesian feature selection to identify only the most relevant biomarkers, effectively filtering out noise.
- Graph Laplacian Prior: Incorporates biological domain knowledge by encoding Linkage Disequilibrium (LD)—the tendency of specific genetic sequences to be inherited together. This encourages the selection of biologically related gene clusters.
- Variational Inference: Employs a coordinate-descent algorithm to make the complex Bayesian computation feasible for large-scale datasets.
Experimental Results
The model was evaluated using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), comprising 618 subjects, 924 SNPs, and 328 MRI features.
Diagnostic Performance
The unified model significantly outperformed existing methods in disease stage prediction. It achieved a 10% improvement over Gaussian Process Ordinal Regression (GPOR) and a 22% improvement over traditional multi-step methods like CCA + Lasso.
Biomarker Discovery
Beyond accuracy, the model identified clinically relevant biomarkers. It highlighted high-confidence genetic markers such as CAPZB, NCOA2, and BCAR3. Furthermore, it successfully mapped these SNPs to atrophy in brain regions critical for memory, such as the middle temporal lobe and precuneus, aligning with established clinical literature. The model's ability to select correlated features in groups (e.g., bilateral brain structures) further validates its biological consistency.
Discussion and Future Work
By linking association discovery directly to clinical labels, the model ensures that identified biomarkers are not just statistically correlated but clinically significant. The use of biological priors helps navigate the "high-dimensional, low-sample-size" problem common in genomic studies.
While the current model is static, future work aims to incorporate longitudinal data to track how these associations evolve over time. Additionally, the framework is extensible and could be expanded to include other data "views," such as proteomic profiles or cognitive test scores, to further enhance diagnostic precision.
Summary updated